An Emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Surgical Oncology Clinics of North America

Volumn 23, Issue 2, 2014, Pages 353-368

  Wo, Jennifer Y ^a   Dawson, Laura A ^b   Zhu, Andrew X ^a   Hong, Theodore S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Hepatobiliary cancers; Radiation therapy; Stereotactic body radiation therapy

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; FLOXURIDINE; PLACEBO; SORAFENIB; SUNITINIB;

ADVANCED CANCER; BILE DUCT CARCINOMA; BREATHING MECHANICS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPUTER ASSISTED RADIOTHERAPY; DIAGNOSTIC IMAGING; DRUG DOSE ESCALATION; HUMAN; ION THERAPY; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTON THERAPY; PORTAL VEIN THROMBOSIS; RADIATION DEPTH DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT PLANNING;

HEPATOBILIARY CANCERS; RADIATION THERAPY; STEREOTACTIC BODY RADIATION THERAPY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; HUMANS; LIVER NEOPLASMS; RADIOSURGERY; RADIOTHERAPY;

EID: 84896739966     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.10.007     Document Type: Review

References (46)

1. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359(9319):1734-1739.
2. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35(5):1164-1171.
3. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359(4):378-390.
4. Tse R.V., Hawkins M., Lockwood G., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. JClin Oncol 2008, 26(4):657-664.
5. Bujold A., Massey C.A., Kim J.J., et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. JClin Oncol 2013, 31(13):1631-1639.
6. Klein J., Dawson L.A. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 2013, 87(1):22-32.
7. Ingold J.A., Reed G.B., Kaplan H.S., et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965, 93:200-208.
8. Russell A.H., Clyde C., Wasserman T.H., et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993, 27(1):117-123.
9. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53(4):810-821.
10. Lawrence T.S., Tesser R.J., ten Haken R.K. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int J Radiat Oncol Biol Phys 1990, 19(4):1041-1047.
11. Ben-Josef E., Normolle D., Ensminger W.D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. JClin Oncol 2005, 23(34):8739-8747.
12. Robertson J.M., Lawrence T.S., Dworzanin L.M., et al. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. JClin Oncol 1993, 11(7):1286-1293.
13. Mornex F., Girard N., Beziat C., et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66(4):1152-1158.
14. Seong J., Lee I.J., Shim S.J., et al. Amulticenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009, 29(2):147-152.
15. Blomgren H., Lax I., Naslund I., et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34(6):861-870.
16. Andolino D.L., Johnson C.S., Maluccio M., et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011, 81(4):e447-e453.
17. Cardenes H.R., Price T.R., Perkins S.M., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010, 12(3):218-225.
18. Kwon J.H., Bae S.H., Kim J.Y., et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010, 10:475.
19. Seo Y.S., Kim M.S., Yoo S.Y., et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. JSurg Oncol 2010, 102(3):209-214.
20. Méndez Romero A., Wunderink W., Hussain S.M., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006, 45(7):831-837.
21. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. JHepatol 2001, 35(3):421-430.
22. Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009, 115(3):616-623.
23. Price T.R., Perkins S.M., Sandrasegaran K., et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012, 118(12):3191-3198.
24. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29(1):62-67.
25. Takagi H., Takayama H., Yamada S., et al. Radiation therapy of hepatocellular carcinoma. Nihon Shokakibyo Gakkai Zasshi 1989, 86(2):237-245. [in Japanese].
26. Xi M., Zhang L., Zhao L., et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013, 8(5):e63864.
27. Rim C.H., Yang D.S., Park Y.J., et al. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. Jpn J Clin Oncol 2012, 42(8):721-729.
28. Yoon S.M., Lim Y.S., Won H.J., et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012, 82(5):2004-2011.
29. Chuma M., Taguchi H., Yamamoto Y., et al. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. JGastroenterol Hepatol 2011, 26(7):1123-1132.
30. Sugahara S., Nakayama H., Fukuda K., et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 2009, 185(12):782-788.
31. Huang Y.J., Hsu H.C., Wang C.Y., et al. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009, 73(4):1155-1163.
32. Lin C.S., Jen Y.M., Chiu S.Y., et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006, 36(4):212-217.
33. Nakayama H., Sugahara S., Tokita M., et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009, 115(23):5499-5506.
34. Bush D.A., Kayali Z., Grove R., et al. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011, 117(13):3053-3059.
35. Kato H., Tsujii H., Miyamoto T., et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004, 59(5):1468-1476.
36. Habermehl D., Debus J., Ganten T., et al. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma-feasibility and clinical response. Radiat Oncol 2013, 8:59.
37. Komatsu S., Fukumoto T., Demizu Y., et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011, 117(21):4890-4904.
38. Sandroussi C., Dawson L.A., Lee M., et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010, 23(3):299-306.
39. Facciuto M.E., Singh M.K., Rochon C., et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. JSurg Oncol 2012, 105(7):692-698.
40. O'Connor J.K., Trotter J., Davis G.L., et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012, 18(8):949-954.
41. Huang C.Y., Lin C.S., Tai W.T., et al. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. Int J Radiat Oncol Biol Phys 2013, 86(3):456-462.
42. Chi K.H., Liao C.S., Chang C.C., et al. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010, 78(1):188-193.
43. Yamada K., Izaki K., Sugimoto K., et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003, 57(1):113-119.
44. Zeng Z.C., Fan J., Tang Z.Y., et al. Acomparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005, 61(2):432-443.
45. Zhang X.B., Wang J.H., Yan Z.P., et al. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer 2009, 115(6):1245-1252.
46. Barney B.M., Olivier K.R., Miller R.C., et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012, 7:67.